Please assess the completion status of the following clinical trial:

Trial Title: Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* received ≥1 treatments for age-related macular degeneration (AMD), diabetic macular edema (DME) or macula edema secondary to branch retinal vein occlusion (BRVO)~Exclusion Criteria:~* baseline diagnosis of glaucoma~* baseline IOP during last visit of greater than 21 mmHg~* ongoing use of topical medications (eg. corticosteroids)~* pseudophakic with an anterior chamber intraocular lens~* history of ocular conditions that may impact IOP (eg. pseudoexfoliation)~* previous in-office (eg. laser peripheral iridotomy) and vitreoretinal surgical procedures (eg. pars plana vitrectomy).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Brimonidine Pre-Administration During First Visit (Type: ACTIVE_COMPARATOR): None
- Brimonidine Pre-Administration During Second Visit (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).